CN107595796A - Pharmaceutical composition of captopril or its salt and preparation method thereof - Google Patents
Pharmaceutical composition of captopril or its salt and preparation method thereof Download PDFInfo
- Publication number
- CN107595796A CN107595796A CN201710774015.7A CN201710774015A CN107595796A CN 107595796 A CN107595796 A CN 107595796A CN 201710774015 A CN201710774015 A CN 201710774015A CN 107595796 A CN107595796 A CN 107595796A
- Authority
- CN
- China
- Prior art keywords
- accounts
- captopril
- gross weight
- salt
- account
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides the pharmaceutical composition of a kind of captopril or its salt, including：Drug core, the first coatings, drug coating layer and optional exterior coating, the drug core include captopril or its salt and pharmaceutical acceptable carrier；First coatings comprise at least PEG, phthalic acid ester and PVA；Drug coating layer comprises at least captopril or its salt, mannitol and microcrystalline cellulose；Exterior coating comprises at least HPMC, PEG and titanium dioxide.The pharmaceutical composition can realize multiple release, reduce patient medication number, avoid morning peak risk, while possess good preparation stability.
Description
Technical field
The invention belongs to field of medicine preparations, and in particular to the pharmaceutical composition of a kind of captopril or its salt and its preparation
Method.
Background technology
Captopril (trade name Captopril, Captopril) is a kind of angiotensin converting enzyme inhibitors (ACE
Inhibitor or ACEI), produced earliest by Bristol-Myers Squibb Co. (Bristol-Myers Squibb), be applied to control
Treat hypertension and certain form of congestive heart failure.As the first ACEI class medicine, due to its new mechanism of action and
Revolutionary development process, it is considered to be the breakthrough in a drug therapy.Since 1977 come out, its anti-hypertension and control
The effect for the treatment of congestive heart failure has been recognized, and has obvious antihypertensive effect to multiple types hypertension, and can improve congested
The cardiac function of heart failure patient.Clinic is applied to all kinds vascular hypertension, serious high blood especially invalid to routine treatment
It is pressed with effect.Also it can be used for intractable chronic heart failure.
At present, captopril is widely used in and faced as a kind of efficiently quick artificial synthesized non-peptides Vel-Tyr-Pro-Trp-Thr-Gln-Arg-Phe
In bed and scientific research.But oral absorption is rapid, about 15min works, and 1h blood concentration peakings are widely distributed.Biological profit
Expenditure 60%, protein binding rate about 30%, T1/2 4h, effect maintain 6-8h.It maintains effect to taken three times per day.Work as intake
When total amount is 37.5~75mg, curative effect only maintains 6~8h；Single oral dose 50mg, peak blood concentrations up to more than 600ng/ml,
And its treatment concentration is 50ng/ml, this larger blood concentration peak valley fluctuation is likely to cause dizziness, headache, intestines and stomach disorderly
The adverse reactions such as unrest (research of captopril sustained release capsules by derivative ultraviolet spectrophotometry, Huang Ying, 2004).Swash due to the effect of captopril medicine is used alone
It is strong, the duration is short, Many researchers turn to sight the research that captopril is sustained, such as the triumphant precious medicine company share in Shanghai is limited
The Captopril Sustained-rdease Tablets of company's production, half-life period 3h.《Institute of Guangdong Pharmaceutical University journal》1997,13 (2), 73~74,
What Lin Huaqing etc. write《The research of the three-dimensional dissolution characteristic and In vitro-in vivo correlation of Captopril Sustained-rdease Tablets》In report Kato
Puli's sustained release tablets, it is intended to extend half-life period, reduce patient's medicining times, but its sustained release can not be controlled.
It presently, there are that some delay the patent of controlled release on captopril or document discloses, such as 201210134299.0, one
Kind carries captopril nanometer fiber slow-releasing body and preparation method thereof；200310109437.0 the controlled release preparation of captopril and its
Preparation method；A kind of 201710216254.0 method for extending captopril hypotensive efficacy time etc..But not yet finding can
Effective controlled release is realized, lifts drug bioavailability, strengthens patient compliance, and drug standard can be met, meets patient
The pharmaceutical preparation of drug safety.
The content of the invention
It is an object of the invention to solve above-mentioned technical problem, there is provided and one kind can effectively realize medicine sustained and controlled release, and
Captopril pharmaceutical composition with preferable bioavilability and medicine stability.
The technical scheme is that carry out in the following manner：
The pharmaceutical composition of the present invention includes：Drug core, the first coatings, drug coating layer and optional outer coatings
Layer.Drug core includes medicine and pharmaceutical acceptable carrier, and the first coatings comprise at least PEG, phthalic acid ester and PVA；Medicine
Coatings comprise at least medicine, mannitol and microcrystalline cellulose；Exterior coating comprises at least HPMC, PEG and titanium dioxide.
Preferably, counted using the gross weight of composition as 100%, the weight proportion of each part is：Drug core accounts for
The 40%-60% of gross weight, the first coatings account for the 5%-20% of gross weight, and drug coating layer accounts for the 20%-50% of gross weight, outside
Coatings account for the 0%-10% of gross weight.
It is furthermore preferred that the weight proportion of each part of composition is：Drug core accounts for the 45%-65% of gross weight, the
One coatings account for the 8%-15% of gross weight, and drug coating layer accounts for the 25%-45% of gross weight, and exterior coating accounts for gross weight
1%-5%.
Most preferably, the weight proportion of each part of composition is：Drug core accounts for the 50% of gross weight, the first coating
Layer accounts for the 13% of gross weight, and drug coating layer accounts for the 35% of gross weight, and exterior coating accounts for the 2% of gross weight.
The further preferred captopril pharmaceutical composition composition of the present invention is with proportioning：
A) drug core：Including captopril or its salt, mannitol, microcrystalline cellulose, magnesium stearate；
B) the first coatings：Including PEG, phthalic acid ester, PVA and talcum powder；
C) drug coating layer：Including captopril or its salt, lactose, microcrystalline cellulose, PEG, HPMC, magnesium stearate and two
Titanium oxide；
D) optionally, exterior coating：Including HPMC, PEG, titanium dioxide and talcum powder.
Preferably, the captopril pharmaceutical composition composition is with proportioning：
A) drug core：Counted using label gross weight as 100%, captopril or its salt accounts for 5%-40%, mannitol accounts for
30%-60%, microcrystalline cellulose account for 25%-60%, magnesium stearate accounts for 0.1%-5%；
B) the first coatings：Counted using the first coatings gross weight as 100%, PEG accounts for 10%-40%, phthalic acid ester
Account for that 20%-50%, PVA account for 30%-60%, talcum powder accounts for 0.1%-5%；
C) drug coating layer：Counted using drug coating layer gross weight as 100%, captopril or its salt account for 8%-50%, breast
Sugar accounts for 10%-40%, microcrystalline cellulose accounts for 10%-40%, PEG and account for 10%-20%, HPMC accounting for 10%-30%, hard
Fatty acid magnesium accounts for 0.1%-5%, titanium dioxide accounts for 0.1%-2%；
D) optionally, exterior coating：Counted using exterior coating gross weight as 100%, HPMC accounts for 30%-80%, PEG and accounted for
15%-70%, titanium dioxide account for 0.1%-2%, and talcum powder accounts for 0.1%-5%.
It is furthermore preferred that the captopril pharmaceutical composition composition is with proportioning：
A) drug core：Counted using label gross weight as 100%, captopril or its salt accounts for 8%-35%, mannitol accounts for
35%-50%, microcrystalline cellulose account for 25%-50%, magnesium stearate accounts for 0.1%-2%；
B) the first coatings：Counted using the first coatings gross weight as 100%, PEG accounts for 25%-35%, phthalic acid ester
Account for that 25%-40%, PVA account for 33%-45%, talcum powder accounts for 0.1%-3%；
C) drug coating layer：Counted using drug coating layer gross weight as 100%, captopril or its salt account for 8%-50%, breast
Sugar accounts for 15%-25%, microcrystalline cellulose accounts for 10%-30%, PEG and account for 10%-15%, HPMC accounting for 12%-30%, hard
Fatty acid magnesium accounts for 0.1%-2%, titanium dioxide accounts for 0.1%-2%；
D) optionally, exterior coating：Counted using exterior coating gross weight as 100%, HPMC accounts for 30%-80%, PEG and accounted for
15%-70%, titanium dioxide account for 0.1%-2%, and talcum powder accounts for 0.1%-2%.
As a kind of preferred scheme, the weight of mannitol and microcrystalline cellulose ratio is 1 in drug core:1-1:3, more preferably
For 1:1、1:2 or 3:4, the weight of lactose and microcrystalline cellulose ratio is 1 in drug coating layer:1-1:3, preferably 1:2.
Particularly preferred, the captopril pharmaceutical composition composition is with proportioning：
A) drug core：Counted using label gross weight as 100%, captopril or its salt account for 8.3%, mannitol and accounted for
45%th, microcrystalline cellulose accounts for 45%, magnesium stearate and accounts for 1.7%；
B) the first coatings：Counted using the first coatings gross weight as 100%, PEG accounts for 30%, phthalic acid ester and accounted for
28%th, PVA accounts for 40%, talcum powder and accounts for 2%；
C) drug coating layer：Counted using drug coating layer gross weight as 100%, captopril or its salt account for 12%, lactose about
Account for 20%, microcrystalline cellulose and account for 30%, PEG and account for 15%, HPMC and account for 20%, magnesium stearate accounting for 1%, titanium dioxide about
Account for 2%；
D) optionally, exterior coating：Counted using exterior coating gross weight as 100%, HPMC accounts for 65%, PEG and accounts for 33%, two
Titanium oxide accounts for 1.5%, and talcum powder accounts for 1.5%.
Or：
A) drug core：Counted using label gross weight as 100%, captopril or its salt account for 16.6%, mannitol and accounted for
41.2%th, microcrystalline cellulose accounts for 41.2%, magnesium stearate and accounts for 1%；
B) the first coatings：Counted using the first coatings gross weight as 100%, PEG accounts for 30%, phthalic acid ester and accounted for
28%th, PVA accounts for 40%, talcum powder and accounts for 2%；
C) drug coating layer：Counted using drug coating layer gross weight as 100%, captopril or its salt account for 24%, lactose about
Account for 20%, microcrystalline cellulose and account for 20%, PEG and account for 13%, HPMC and account for 20%, magnesium stearate accounting for 1%, titanium dioxide about
Account for 2%；
D) optionally, exterior coating：Counted using exterior coating gross weight as 100%, HPMC accounts for 65%, PEG and accounts for 33%, two
Titanium oxide accounts for 1.5%, and talcum powder accounts for 1.5%.
Or：
A) drug core：Counted using label gross weight as 100%, captopril or its salt account for 16.6%, mannitol and accounted for
27.4%th, microcrystalline cellulose accounts for 55%, magnesium stearate and accounts for 1%；
B) the first coatings：Counted using the first coatings gross weight as 100%, PEG accounts for 30%, phthalic acid ester and accounted for
28%th, PVA accounts for 40%, talcum powder and accounts for 2%；
C) drug coating layer：Counted using drug coating layer gross weight as 100%, captopril or its salt account for 24%, lactose about
Account for 13.3%, microcrystalline cellulose and account for 26.7%, PEG and account for 13%, HPMC and account for 20%, magnesium stearate accounting for 1%, titanium dioxide
Titanium accounts for 2%；
D) optionally, exterior coating：Counted using exterior coating gross weight as 100%, HPMC accounts for 65%, PEG and accounts for 33%, two
Titanium oxide accounts for 1.5%, and talcum powder accounts for 1.5%.
Or：
A) drug core：Counted using label gross weight as 100%, captopril or its salt account for 33%, mannitol account for 33%,
Microcrystalline cellulose accounts for 33%, magnesium stearate and accounts for 1%；
B) the first coatings：Counted using the first coatings gross weight as 100%, PEG accounts for 30%, phthalic acid ester and accounted for
28%th, PVA accounts for 40%, talcum powder and accounts for 2%；
C) drug coating layer：Counted using drug coating layer gross weight as 100%, captopril or its salt account for 47.6%, lactose
Account for 12%, microcrystalline cellulose and account for 12%, PEG accounting for 10%, HPMC and account for 16%, magnesium stearate accounting for 1%, titanium dioxide
Account for 1.4%；
D) optionally, exterior coating：Counted using exterior coating gross weight as 100%, HPMC accounts for 65%, PEG and accounts for 33%, two
Titanium oxide accounts for 1.5%, and talcum powder accounts for 1.5%.
As a kind of preferred scheme, the total tablet weight of pharmaceutical composition of the present invention is 300mg, respective independent, drug core
It is 12.5mg, 25mg or 50mg with the content of captopril or its salt in drug coating layer.
The present invention also aims to provide a kind of preparation method of described pharmaceutical composition, methods described includes：With straight
Platen press prepares label, and the first coatings are sprayed on the label, prepares the suspension of drug coating layer, and is coated on
Above-mentioned first coatings outer layer, further, outer layer coating layer is coated on drug coating layer outer layer with the coating method of routine.
The pharmaceutical composition of the present invention has the following advantages that：
1st, discharged and designed by multilayer medicine, realize the long-acting slow-release effect of medicine, in outer layer insoluble drug release and rapid
After playing drug effect, after time-delay, then the medicine in label is discharged, used twice so as to realize to reach after single medication
The antihypertensive effect of medicine, patient medication number is reduced, while after night takes, the morning peak phenomenon of hypertension can be avoided.
2nd, by specific prescription screening, the bioavilability of medicine is improved, it is necessary to overcome the general tablet of in the market
The limitation taken before the meal, reduce influence of the food to insoluble drug release.
3rd, medicine has good result of extraction and preparation stability, meets the security requirement of patient medication.
Figure of description
Fig. 1 writes music line to take drug absorption in the beasle dog body of the pharmaceutical composition of the embodiment of the present invention 3 before the meal；
Fig. 2 takes drug absorption in the beasle dog body of the pharmaceutical composition of the embodiment of the present invention 3 and write music line after the meal.
Embodiment
Content for a better understanding of the present invention, technical scheme is done below in conjunction with specific embodiment into
One step describes, but the protection content of the present invention is not limited to specific embodiment.
Embodiment 1 (piece weight 300mg, 25mg specifications)
Preparation prescription：
A) drug core 150mg
Captopril 25mg, mannitol 61.8mg, microcrystalline cellulose 61.8mg, magnesium stearate 1.4mg；
B) the first coatings 40mg
PEG12mg, phthalic acid ester 11.2mg, PVA16mg, talcum powder 0.8mg；
C) drug coating layer 105mg
Captopril 25mg, lactose 21mg, microcrystalline cellulose 21mg, PEG 13.7mg, HPMC 21mg, magnesium stearate
1.2mg, titanium dioxide 2.1mg；
D) exterior coating 5mg
HPMC 3.25mg, PEG 1.6mg, titanium dioxide 0.075mg, talcum powder 0.075mg.
Preparation production technique：
Label is prepared, captopril, mannitol and microcrystalline cellulose are premixed, the magnesium stearate added after pre-sifted
Mixed, label is made in mixture punching press with tablet press machine.
Component in first coatings is added in 0.1N hydrochloric acid and stirred, the suspension of the first coatings, adjustment is made
PH of suspension is 2-3, above-mentioned uniform suspension is coated on to label outer layer with seed-coating machine, heat drying obtains preparation intermediate
A。
Captopril in drug coating layer and other auxiliary materials are added to stirring to obtain even suspension in 0.1N hydrochloric acid
Liquid, adjustment pH of suspension are 2-3, and the uniform suspension of drug coating layer is coated on into above-mentioned preparation intermediate A with seed-coating machine
Outer layer, heat drying to constant weight obtain preparation intermediate B.
The prescription component of exterior coating is added to stirring to obtain unit for uniform suspension in 0.1N hydrochloric acid, adjusts pH of suspension
For 2-3, the uniform suspension of exterior coating is coated on to the outer layer of above-mentioned preparation intermediate B, heat drying to perseverance with seed-coating machine
Weight.
Embodiment 2 (piece weight 300mg, 25mg specifications)
The production technology of reference implementation example 1, prepare agents preparation
Embodiment 3 (piece weight 300mg, 25mg specifications)
The production technology of reference implementation example 1, prepare agents preparation
Embodiment 4 (piece weight 300mg, 12.5mg specifications)
The production technology of reference implementation example 1, prepare agents preparation
The drug absorption degree of experimental example 1 is tested
The 25mg specifications preparation (empty stomach) of the embodiment of the present invention 3 is given to 6 beasle dogs, every dog is administered 1, respectively at
0.5 after administration, 1.0,2.0,3.0,4.0,5.0,6.0,7.0,8.0,9.0,10.0,11.0,12.0,13.0,14.0,15.0,
Time point of 16.0 hours extracts blood sample, determines the blood concentration (n=6) of different time points, abscissa t=h, and ordinate is average
Blood concentration is μ g/L.
It will be seen from figure 1 that after invention formulation administration 12 as a child interior have absorb twice, and then realize night
Avoid the morning peak of morning drug failure dangerous after administration, while can realize that administration is kept to be administered twice daily 3 times a day, is lifted
The convenience of medication.
The dining of experimental example 2 influences experiment
The 25mg specification preparations of the embodiment of the present invention 3 are given with 6 beasle dogs of experimental example 1, difference is feeding
It is administered in half an hour after, every dog is administered 1, according to the identical point in time sampling of experimental example 1, determines blood concentration, as a result such as
Shown in Fig. 2.
In terms of comparing result, if dining does not influence on the absorption for taking pharmaceutical preparation of the present invention.
The preparation stability of experimental example 3 is tested
(1) accelerated test
By invention formulation with being placed on 40 ± 2 DEG C after In Aluminium Foil Packing, 6 in the climatic chamber of relative humidity 75 ± 5%
Individual month, total miscellaneous and maximum miscellaneous content of list is determined, as a result as shown in table 1.
Table 1：Accelerated test result
(2) long-term stable experiment
By invention formulation with being placed on 25 ± 2 DEG C after In Aluminium Foil Packing, under conditions of relative humidity 60 ± 10%, respectively at
0th, sampling detection in 3,6,9,12,18 months, investigates sample long-time stability, as a result as shown in table 2.
Table 2：Long-term stable experiment result
Result is investigated by the preparation stability of Tables 1 and 2 and can be seen that the captopril preparation of the present invention with good
Stability, meet drug standard, the drug safety of patient can be ensured.
Claims (10)
1. the pharmaceutical composition of a kind of captopril or its salt, including：Drug core, the first coatings, drug coating layer and appoint
The exterior coating of choosing, the drug core include captopril or its salt and pharmaceutical acceptable carrier；First coatings comprise at least
PEG, phthalic acid ester and PVA；Drug coating layer comprises at least captopril or its salt, mannitol and microcrystalline cellulose；Outside
Coatings comprise at least HPMC, PEG and titanium dioxide.
2. the pharmaceutical composition of captopril according to claim 1 or its salt, it is characterised in that with the gross weight of composition
Measure and be for 100% meter, the weight proportion of each part：Drug core accounts for the 40%-60% of gross weight, and the first coatings account for gross weight
5%-20%, drug coating layer accounts for the 20%-50% of gross weight, and exterior coating accounts for the 0%-10% of gross weight.
3. the pharmaceutical composition of captopril according to claim 1 or its salt, it is characterised in that with the gross weight of composition
Measure and be for 100% meter, the weight proportion of each part：Drug core accounts for the 45%-65% of gross weight, and the first coatings account for gross weight
8%-15%, drug coating layer accounts for the 25%-45% of gross weight, and exterior coating accounts for the 1%-5% of gross weight.
4. the pharmaceutical composition of captopril according to claim 1 or its salt, it is characterised in that with the gross weight of composition
Measure and be for 100% meter, the weight proportion of each part：Drug core accounts for the 50% of gross weight, and the first coatings account for gross weight
13%, drug coating layer accounts for the 35% of gross weight, and exterior coating accounts for the 2% of gross weight.
5. the pharmaceutical composition of captopril according to claim 1 or its salt, it is characterised in that the composition prescription
Form with proportioning and be：
A) drug core：Including captopril or its salt, mannitol, microcrystalline cellulose and magnesium stearate；
B) the first coatings：Including PEG, phthalic acid ester, PVA and talcum powder；
C) drug coating layer：Including captopril or its salt, lactose, microcrystalline cellulose, PEG, HPMC, magnesium stearate and titanium dioxide
Titanium；
D) optionally, exterior coating：Including HPMC, PEG, titanium dioxide and talcum powder.
6. the pharmaceutical composition of captopril according to claim 5 or its salt, it is characterised in that the composition prescription
Form with proportioning and be：
A) drug core：Counted using label gross weight as 100%, captopril or its salt accounts for 5%-40%, mannitol accounts for 30%-
60%th, microcrystalline cellulose accounts for 25%-60%, magnesium stearate 0.1%-5%；
B) the first coatings：Counted using the first coatings gross weight as 100%, PEG accounts for 10%-40%, phthalic acid ester accounts for 20%-
50%th, PVA accounts for 30%-60%, talcum powder accounts for 0.1%-5%；
C) drug coating layer：Counted using drug coating layer gross weight as 100%, captopril or its salt accounts for 8%-50%, lactose accounts for
10%-40%, microcrystalline cellulose account for 10%-40%, PEG and account for that 10%-20%, HPMC account for 10%-30%, magnesium stearate accounts for
0.1%-5%, titanium dioxide account for 0.1%-2%；
D) optionally, exterior coating：Counted using exterior coating gross weight as 100%, HPMC account for 30%-80%, PEG account for 15%-70%,
Titanium dioxide accounts for 0.1%-2%, and talcum powder accounts for 0.1%-5%.
7. the pharmaceutical composition of captopril according to claim 5 or its salt, it is characterised in that sweet dew in drug core
The weight of alcohol and microcrystalline cellulose ratio is 1:1-1:3, preferably 1:1、1:2 or 3:4；Lactose and microcrystalline cellulose in drug coating layer
Weight ratio be 1:1-1:3, preferably 1:2.
8. the pharmaceutical composition of captopril according to claim 5 or its salt, it is characterised in that the composition prescription
Form with proportioning and be：
A) drug core：Counted using label gross weight as 100%, captopril or its salt account for 16.6%, mannitol account for 27.4%,
Microcrystalline cellulose accounts for 55%, magnesium stearate and accounts for 1%；
B) the first coatings：Counted using the first coatings gross weight as 100%, PEG account for 30%, phthalic acid ester account for 28%,
PVA accounts for 40%, talcum powder and accounts for 2%；
C) drug coating layer：Counted using drug coating layer gross weight as 100%, captopril or its salt account for 24%, lactose and accounted for
13.3%th, microcrystalline cellulose accounts for 26.7%, PEG and accounts for 13%, HPMC and account for 20%, magnesium stearate accounting for 1%, titanium dioxide
Account for 2%；
D) optionally, exterior coating：Counted using exterior coating gross weight as 100%, HPMC accounts for 65%, PEG and accounts for 33%, titanium dioxide
Titanium accounts for 1.5%, and talcum powder accounts for 1.5%.
9. the pharmaceutical composition of captopril according to claim 1 or its salt, it is characterised in that pharmaceutical composition it is total
Piece weight is 300mg, each it is independent, in drug core and drug coating layer the content of captopril or its salt be 12.5mg,
25mg or 50mg.
10. the method for preparing claim 1-9 any one captopril or the pharmaceutical composition of its salt, including：Use direct pressure closing
Drug core is prepared, the first coatings are made after suspension and are sprayed on the drug core, prepares the outstanding of drug coating layer
Supernatant liquid, and the first coatings outer layer is coated on, optional, in addition to exterior coating is coated on drug coating layer outer layer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710774015.7A CN107595796A (en) | 2017-08-31 | 2017-08-31 | Pharmaceutical composition of captopril or its salt and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710774015.7A CN107595796A (en) | 2017-08-31 | 2017-08-31 | Pharmaceutical composition of captopril or its salt and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107595796A true CN107595796A (en) | 2018-01-19 |
Family
ID=61055938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710774015.7A Pending CN107595796A (en) | 2017-08-31 | 2017-08-31 | Pharmaceutical composition of captopril or its salt and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107595796A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
| CN1546018A (en) * | 2003-12-10 | 2004-11-17 | 杭州民生药业集团有限公司 | Controlled release preparation of captopril and its preparation process |
| US20060003404A1 (en) * | 2002-02-05 | 2006-01-05 | Deb Jahar K | Method for specific integration of t7 rna polymerase gene in the chromosome of corynebacterial and the resultant corynebacteria-t7 promoter based shuttle vector system |
| CN101090718A (en) * | 2004-12-30 | 2007-12-19 | 韩美药品株式会社 | Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductase inhibitor and antihypertensive agent, and process for preparing same |
-
2017
- 2017-08-31 CN CN201710774015.7A patent/CN107595796A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
| US20060003404A1 (en) * | 2002-02-05 | 2006-01-05 | Deb Jahar K | Method for specific integration of t7 rna polymerase gene in the chromosome of corynebacterial and the resultant corynebacteria-t7 promoter based shuttle vector system |
| CN1546018A (en) * | 2003-12-10 | 2004-11-17 | 杭州民生药业集团有限公司 | Controlled release preparation of captopril and its preparation process |
| CN101090718A (en) * | 2004-12-30 | 2007-12-19 | 韩美药品株式会社 | Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductase inhibitor and antihypertensive agent, and process for preparing same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190183883A1 (en) | Sustained Release Formulation Of Naltrexone | |
| JP5775464B2 (en) | Delayed release oral dosage composition containing amorphous CDDO-ME | |
| MXPA04010496A (en) | High drug load tablet. | |
| WO2022022369A1 (en) | Sustained-release formulation of tofacitinib or salt thereof and preparation method therefor | |
| JP6174666B2 (en) | Naltrexone sustained release formulation | |
| WO2004054574A1 (en) | Solid drug for oral use | |
| WO2004037203A9 (en) | Sustained release l-arginine formulations and methods of manufacture and use | |
| AU2013209610B2 (en) | Methods and formulations for treating sialic acid deficiencies | |
| CN104825416B (en) | disulfiram implant and preparation method thereof | |
| CN104940152B (en) | A kind of pharmaceutical composition containing butanedioic acid Solifenacin | |
| CN104127391B (en) | A kind of contain Atorvastatin calcium solid composite medicament | |
| EP3302483B1 (en) | Pharmaceutical compositions and use thereof | |
| WO2013189305A1 (en) | Valsartan-amlodipine compound solid preparation and preparation method therefor | |
| CN107595796A (en) | Pharmaceutical composition of captopril or its salt and preparation method thereof | |
| Farah et al. | The influence of khat on the in-vitro and in-vivo availability of tetracycline-HCl | |
| JP2014111564A (en) | Sinomenium stem containing composition | |
| WO2007143290A2 (en) | Delayed-release compositions of extended release forms of venlafaxine | |
| CN102349906B (en) | Atorvastatin calcium and nicotinic acid composition and preparation method thereof | |
| CN109758432A (en) | A kind of Diflunisal enteric coatel tablets and preparation method thereof | |
| RU2506947C2 (en) | Prolonged release tablet containing theobromin | |
| CN106474095A (en) | A kind of for treating oral mucosa alite paste of oral mykoses and preparation method thereof | |
| AU2021291437A1 (en) | Acalabrutinib maleate dosage forms | |
| Gaikwad et al. | Formulation, Development and Evaluation of Bilayer Tablet of Flurbiprofen | |
| WO2012062691A1 (en) | Pharmaceutical compositions for treating hcv infections | |
| Toskić-Radojčić et al. | A comparative analysis of the influence of different types of Carbopol® on the release rate of lithium-carbonate from matrix tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 430040 Room 509, Unit 1, Workshop No. 1, Accelerator Phase I Project of Wuhan Guanggu International Biomedical Enterprise, No. 388, Donghu New Technology Development Zone, Wuhan City, Hubei Province Applicant after: Wuhan Jiuzhou Yumin Medical Technology Co., Ltd. Address before: 430000 East Lake New Technology Development Zone, Wuhan, Hubei 388, No. 388 hi tech two road, Wuhan Optics Valley international biomedical enterprise accelerator phase 1 workshop No. 1, unit 509. Applicant before: Wuhan Yu Yu Yu Pharmaceutical Technology Co., Ltd. |
|
| CB02 | Change of applicant information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180119 |
|
| RJ01 | Rejection of invention patent application after publication |